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Background: There are only scarce data about the benefit of adjunctive chemotherapy in patients with localized
synovial sarcoma (SS).
Patients and methods: Data from 237 SS patients recorded in the database of the French Sarcoma Group were
retrospectively analyzed. The respective impact of radiotherapy, neo-adjuvant chemotherapy and adjuvant
chemotherapy on overall survival (OS), local recurrence-free survival (LRFS) and distant recurrence-free survival (DRFS)
were assessed after adjustment to prognostic factors.
Results: The median follow-up was 58 months (range 1–321). Adjuvant, neo-adjuvant chemotherapy and
postoperative radiotherapy were administered in 112, 45 and 181 cases, respectively. In all, 59% of patients treated
with chemotherapy received an ifosfamide-containing regimen. The 5-year OS, LRFS and DRFS rates were 64.0%,
70% and 57%, respectively. On multivariate analysis, age >35 years old, grade 3 and not-R0 margins were highly
significant independent predictors of worse OS. After adjustment to prognostic factors, radiotherapy significantly
improved LRFS but not DRFS or OS. Neither neo-adjuvant nor adjuvant chemotherapy had significant impact on OS,
LRFS or DRFS.
Conclusion: As for other high-grade soft-tissue sarcomas, well-planned wide surgical excision with adjuvant
radiotherapy remains the cornerstone of treatment for SS. Neo-adjuvant or adjuvant chemotherapy should not be
delivered outside a clinical trial setting.
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introduction
Synovial sarcoma (SS) accounts for 6%–9% of soft-tissue
sarcomas and is most prevalent in adolescents and young adults
15–35 years of age [1–7]. This aggressive tumor is characterized
by a high rate of local and metastatic recurrences which occur
in 40%–50% of patients usually within 2 years after the initial
diagnosis [4, 5]. Well-planned wide surgical excision
complemented by radiotherapy in cases of large tumors or
invaded margins is the standard for the locoregional treatment
of these tumors [8]. As for other high-grade soft-tissue sarcoma
subtypes, neo-adjuvant/adjuvant chemotherapy is also widely
used in order to decrease the risk of developing a distant
recurrence related to the existence of subclinical
micrometastasis at presentation [9]. However, several
randomized controlled trials [10–12] as well as a meta-analysis
based on individual data [13] have shown that neo-adjuvant or
adjuvant systemic chemotherapy do not improve survival
significantly in patients with soft-tissue sarcomas. Despite the
fact that >50 different sarcoma subtypes exist, soft-tissue
sarcomas were considered as a single pathological entity in
most of these trials. Therefore, it cannot be excluded that
o
ri
g
in
a
l
a
rt
ic
le
*Correspondence to: Dr A. Italiano, Department of Medical Oncology, Institut Bergonie´,
229 cours de l’Argonne, 33076 Bordeaux Cedex, France. Tel: +33-05-56-33-33-33;
Fax: +33-05-56-33-33-30; E-mail: italiano@bergonie.org
These authors contributed equally to the work and must be considered as two first
coauthors.
ª The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
neo-adjuvant or adjuvant chemotherapy reduces the risk of
recurrence and may increase the rate of survival among patients
with specific subtypes of soft-tissue sarcomas with a particular
biological profile. SS is considered as a chemosensitive disease
on the basis of the results of trials carried out in the advanced
[14–17] or the pediatric setting [18, 19]. There are only scarce
and conflicting data about the benefit of neo-adjuvant or
adjuvant chemotherapy in patients with localized SS. Although
two series including a small number of treated patients (n = 68
[20] and 61 [17], respectively) have suggested a benefit of
adjuvant chemotherapy in terms of disease-specific [20] or
metastasis-free survival [17], one other study (n = 42) has
reported no improvement of metastatic failure rate and tumor-
related mortality [5].
The aim of our study is to clarify the prognosis factors and
the impact of neo-adjuvant/adjuvant chemotherapy for adult
patients with localized SS. To this aim, we have carried out an
extensive analysis of the database of the French Sarcoma Group
on a series of 237 patients with centrally reviewed SS.
patients and methods
patients
From 1974 to 2006, 261 nonpediatric patients (‡15 years old) with a SS
were admitted to one of the 17 tertiary cancer centers of the French
Sarcoma Group for the management of a first tumoral event. Clinical and
pathologic data were collected by reviewing medical records at each
institution and were then entered into a comprehensive database. Twenty-
four patients were excluded from the analysis because of metastatic disease
at the time of diagnosis and/or no surgical treatment of the primary lesion.
The histological diagnosis was reviewed for all specimens by a panel of
experts of the French Sarcoma Group. In all cases, the diagnosis of SS was
confirmed, according to the World Health Organization Classification of
Tumors [21]. The histological grade was determined as previously
described according to the Fe´de´ration Nationale des Centres de Lutte
Contre le Cancer grading system [22]. A tumor could be either grade 2 or
grade 3, depending on mitotic rate, the extent of necrosis or both. The
margin status was classified as R0 (macroscopically and microscopically
clear), R1 (macroscopically clear and microscopically involved) or
uncertain (macroscopically clear and microscopically narrow margins of <1
mm). Absolute dose intensity of doxorubicine (mg/m2/week) and
ifosfamide (g/m2/week) was determined as previously described [23, 24].
statistical analysis
The statistical analysis of baseline demographics and clinical outcome
are based on all data available up to the cut-off date of 30 April 2008.
Overall survival (OS) was defined as the interval between diagnosis and
the time of death or last follow-up. Local recurrence-free survival (LRFS)
was defined as the interval between diagnosis and the time of local
recurrence or the last follow-up. Distant recurrence-free survival (DRFS)
was defined as the interval between diagnosis and the time of distant
recurrence or the last follow-up. Survival rates were estimated with the use
of the Kaplan–Meier method and compared using the log-rank test [26].
Descriptive statistics were used to show the distribution of variables in the
population. Univariate and multivariate analyses were carried out by Cox
regression. Variables associated with survival with a P value <0.05 in the
univariate analysis were included in the multivariate regression. Analyses
were carried out using SPSS 14.0 statistical software (IPSS Inc., Chicago).
All statistical tests were two sided, and P < 0.05 indicated statistical
significance.
results
patients
The study population included 237 patients (117 men and 120
women). The median age was 35 years (range 15–76). Their
characteristics are described in Table 1.
treatment delivery
All patients underwent complete surgical resection of their
primary tumor. Adjuvant radiation therapy was delivered in
181 cases (76%) according to local practice guidelines (Table
1). Neo-adjuvant chemotherapy and adjuvant chemotherapy
were delivered in 45 cases (19%) and 112 cases (47%),
respectively. Fifteen patients (6%) received both neo-adjuvant
and adjuvant chemotherapy. Several treatment regimens and
dosages have been used during the study period. All the
patients with available data (n = 117) received an
Table 1. Patients characteristics (n = 237)
n %
Sites of involvement
Lower limb 155 65.4
Upper limb 50 21.1
Trunk 15 6.3
Abdominal wall 11 4.6
Head and neck 2 0.8
Others 4 1.7
Grade
2 112 47.2
3 125 52.8
Tumor size, cm
Median 7
Range 1–35
Margin status
R0 90 38.0
Uncertain margin 53 22.3
R1 35 14.8
Unknown 59 24.9
Patterns of neo-adjuvant and adjuvant treatments (n = 237)
n %
Adjuvant radiotherapy
Yes 181 76.4
No 56 23.6
Neo-adjuvant chemotherapya
Yes 45 19.0
No 192 81.0
Anthracycline-based regimen 34 14.3
Ifosfamide-based regimen 34 14.3
Unknown regimen 6 2.5
Adjuvant chemotherapya
Yes 112 47.3
No 125 52.7
Anthracycline-based regimen 86 36.3
Ifosfamide-based regimen 62 26.2
Unknown regimen 20 8.4
aFifteen patients received both neo-adjuvant and adjuvant chemotherapy.
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anthracycline- and/or an ifosfamide-containing regimen.
Eighty-four patients (59%) received an ifosfamide-containing
regimen. The median number of cycles was 4 (range 2–8) in the
neo-adjuvant setting and 5 (range 1–11) in the adjuvant setting.
The median dose intensity of doxorubicin was 19 and 15 mg/
m2/week in the neo-adjuvant setting and in the adjuvant
setting, respectively. The median dose intensity of ifosfamide
was 2.3 and 1.6 g/m2/week in the neo-adjuvant setting and in
the adjuvant setting, respectively. The median total dose of
doxorubicin and of ifosfamide was 298 mg/m2 (range 0–507)
and 29 g/m2 (range 0–56), respectively.
overall survival (Figure 1)
The median follow-up was 58 months (range 1–321). At the
time of analysis (30 April 2008), 98 patients (41.5%) had died
and 129 (54.5%) were still alive (Tables 2 and 3). Ten patients
(4%) were lost to follow-up. Ninety-three deaths were the
result of SS and five the result of other causes. One death (1%)
was related to treatment (septic shock after the first cycle of
adjuvant chemotherapy). The median OS was 136 months
[95% confidence interval (CI) 70–204]. The 1-year, 5-year
and 9-year OS rates were 85.0% (95% CI 82–88), 64% (95% CI
59–69) and 46% (95% CI 40–52), respectively. On univariate
analysis, age >35 years old, extra-limb locations, tumor size >7
cm, grade 3 and not-R0 margins were adverse prognostic
factors for OS. On multivariate analysis, age >35 years old,
grade 3 and not-R0 margins remained highly significant
independent predictors of worse OS.
local recurrence-free survival (Figure 1)
At the time of analysis (30 April 2008), 56 patients (23.5%) had
local recurrence (Tables 2 and 3). The median LRFS was not
reached. The 1-year, 5-year and 9-year LRFS rates were 94%
(95% CI 92% to 96%), 70% (95% CI 64% to 76%) and 69%
(95% CI 64% to 73%), respectively. The median time to local
recurrence was 18 months. Eighteen patients had local
recurrence occurring >2 years after the initial diagnosis. Median
survival from the time of recurrence was longer for patients
with late local recurrence (>2 years from the time of diagnosis)
than for patients with earlier treatment failure (54 versus 24
months, P = 0.022). On univariate analysis, extra-limb
locations, grade 3 and not-R0 margins were adverse prognostic
factors for LRFS. On multivariate analysis, not-R0 margins
remained the sole independent predictor of worse LRFS.
distant recurrence-free survival (Figure 1)
At the time of analysis (30 April 2008), 106 patients (45%) had
distant recurrence (Tables 2 and 3). The median DRFS was 121
months (95% CI 101–141). The 1-year, 5-year and 9-year DRFS
rates were 80% (95% CI 77% to 84%), 57% (95% CI 53% to
62%) and 46% (95% CI 41% to 51%), respectively. The median
time to distant recurrence was 20 months. Forty-three patients
had distant recurrence occurring >2 years after the initial
diagnosis. Median survival from the time of recurrence was
longer for patients with late distant recurrence (>2 years from
the time of diagnosis) than for patients with earlier treatment
failure (27 versus 15 months, P = 0.0001). On univariate
analysis, age >35 years old, tumor size >7 cm, extra-limb
locations and grade 3 were adverse prognostic factors for DRFS.
On multivariate analysis, age >35 years old, tumor size >7 cm,
and grade 3 remained independent predictors of worse DRFS.
impact of adjuvant radiotherapy on outcome =
The impact of adjuvant radiotherapy was analyzed after
adjustment to the respective variables associated with OS,
DFRS and LRFS on multivariate analysis (Table 4). Adjuvant
radiotherapy significantly improved LRFS but not OS or DRFS.
impact of neo-adjuvant and adjuvant
chemotherapy on outcome
Neither neo-adjuvant chemotherapy nor adjuvant
chemotherapy had a significant impact on OS, LRFS or DRFS
after adjustment to the prognostic factors identified on
multivariate analysis (Table 4).
discussion
We have reported here the largest series to date describing the
outcome of nonpediatric patients with localized SS.
The 5-year OS (64%) and DRFS (57%) rates as well as the
proportion of patients with local recurrence (23.5%) were
similar to that reported by Ferrari et al. [17] in a series of 215
patients (including 41 pediatric cases) with SS treated by
Figure 1. Kaplan–Meier curves for local recurrence-free survival (A), distant recurrence-free survival (B) and overall survival (C) of the entire cohort study
(n = 237).
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complete surgical resection (70.6%, 51.1% and 30%,
respectively). Although the majority of local (68%) or distal
recurrence (59.5%) occurred within 2 years after the initial
diagnosis, a significant proportion of patients experienced late
treatment failure up to 15 years after initial diagnosis. This
underscores the need for a prolonged follow-up of patients with
primary resected SS. Interestingly, patients with recurrence
occurring >2 years after the initial diagnosis had a significantly
better outcome than patients who relapsed earlier. Such
a correlation between a longer time to recurrence and a better
postrecurrence survival has been already reported for Ewing
sarcomas [25], osteosarcomas [26] and in a series of 255
patients who underwent complete resection of lung metastases
from soft-tissue sarcomas [27]. Nevertheless, our findings
should be interpreted with caution. The time to recurrence was
not significantly associated with outcome in a recent study
including 104 patients with advanced SS treated at the Royal
Marsden Hospital [28]. Moreover, the design of our study did
not allow us to analyse the impact on postrecurrence survival of
several key variables such as the type of management of local
recurrence, the role of resection of metastases or the role of an
additional line of chemotherapy in patients with metastatic
relapse already treated with chemotherapy in the adjuvant
setting.
The large cohort included in our study as well as the mature
follow-up allowed us to identify robust prognostic factors for
patients with localized SS. In our series, grade 3, age >35 years
and not-R0 margin status were independent predictors of poor
OS. These findings were consistent with the data from smaller
series which have already shown a significant correlation of
grade [22] and age [29] with outcome. We have also found that
the margin status was the strongest predictive factor of local
recurrence as previously reported in other soft-tissue sarcoma
subtypes [2]. Some factors such as the histological subtype
(monophasic, biphasic or undifferentiated) [20] or the fusion
type (SYT-SSX1 or SYT-SSX2) resulting from the characteristic
translocation t(X;18) [21] were not analyzed since they were
not available for the majority of the patients included in our
database. However, these two factors are not independent since
most biphasic cases contain the SYT-SSX1 fusion type [22, 31,
32]. Moreover, their prognostic value is still highly
Table 3. Independent prognostic factors for OS, LRFS and DRFS: multivariate analysis (n = 237)
Variables Adjusted hazard ratio for OS Adjusted hazard ratio for LRFS Adjusted hazard ratio for DMFS
Age >35 2.16 (1.28–3.64), P = 0.004 – 1.56 (1.05–2.34), P = 0.028
Grade 3 4.07 (2.22–7.40), P = 0.0001 – 3.01 (1.92–4.74), P = 0.0001
R0 1 1
Uncertain margin 2.43 (1.34–4.54), P = 0.005 2.43 (1.11–5.26), P = 0.027 –
R1 2.56 (1.29–5.26), P = 0.007 2.44 (1.01–5.88), P = 0.050 –
Size >7 cm – – 2.15 (1.41–3.26), P = 0.0001
OS, overall survival; LRFS, local recurrence-free survival; DRFS, distant recurrence-free survival.
Table 4. Impact of neo-adjuvant and adjuvant treatments on OS, LRFS and DRFS after adjustment to prognostic factors: multivariate analysis (n = 237)
Adjusted hazard ratio for OSa Adjusted hazard ratio for LRFSb Adjusted hazard ratio for DRFSc
Adjuvant radiotherapy 1.01 (0.75–2.00), P = 0.358 0.43 (0.22–0.90), P = 0.026 0.78 (0.33–4.13), P = 0.499
Neo-adjuvant chemotherapy 0.91 (0.56–1.49), P = 0.725 0.47 (0.16–1.34), P = 0.160 1.37 (0.89–2.18), P = 0.175
Adjuvant chemotherapy 1.62 (0.91–2.87), P = 0.099 0.81 (0.45–1.71), P = 0.710 0.93 (0.63–1.38), P = 0.738
aOS was adjusted to age >35, grade 3 and surgical margins (see Table 4).
bLRFS was adjusted to surgical margins (see Table 4).
cDRFS was adjusted to age >35, grade 3 and size >7 cm (see Table 4).
OS, overall survival; LRFS, local recurrence-free survival; DRFS, distant recurrence-free survival.
Table 2. Prognostic factors for OS, LRFS and DRFS: univariate analysis
(n = 237)
Variables Median
OS
(months)
P Median
LRFS
(months)
P Median
DRFS
(months)
P
Male 136 NR 144
Female 126 0.931 NR 0.888 121 0.660
Age £ 35 NR NR NR
Age> 35 79 0.0001 NR 0.102 59 0.018
Limb 160 NR NR
Extra-limb 46 0.0001 NR 0.0001 48 0.0001
Size £7 cm 232 NR NR
Size >7 cm 127 0.0001 NR 0.141 23 0.0001
Grade 2 NR NR NR
Grade 3 69 0.0001 NR 0.020 29 0.0001
R0 NR NR NR
Uncertain
margin
160 0.01 NR 191
R1 52 NR 0.043 27 0.129
OS, overall survival; LRFS, local recurrence-free survival; DRFS, distant
recurrence-free survival; NR, not reached.
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controversial and some authors suggest that it if exists, it is
overshadowed by more relevant parameter such as grade [22,
31, 32].
The role of adjuvant and or neo-adjuvant chemotherapy in
soft-tissue sarcomas is a matter of debate. A 1997 individual
patient meta-analysis of all known randomized clinical data
failed to show a significant benefit of adjuvant chemotherapy in
terms of OS [13]. A subsequent phase III study involving 104
patients with resectable high-grade/large (>5 cm) or recurrent
limb soft-tissue sarcoma showed a statistically significant
benefit for OS being 13% and 19% at 2 and 4 years,
respectively, in the group treated with an intensified
anthracycline/ifosfamide combination [33]. However, this
benefit of adjuvant chemotherapy in terms of OS rate has lost
its statistical significance with further follow-up [34]. Such lack
of benefit of adjuvant chemotherapy has recently been
confirmed in a larger trial involving 351 patients and who were
randomly allocated to receive chemotherapy with five cycles of
doxorubicin 75 mg/m2, ifosfamide 5 g/m2 every 21 days and
lenograstim or a simple surveillance after the locoregional
treatment of a soft-tissue sarcoma [11]. Estimated 5-year
relapse-free survival was 52% in both groups, and OS was 69%
in the observational group versus 64% in the chemotherapy
group (hazard ratio = 0.621 for both). Moreover, the sole
randomized trial ever conducted in the neo-adjuvant setting
has also shown no survival advantage in those patients treated
with a doxorubicin/ifosfamide-based regimen [12]. Some
authors argue that the apparent lack of benefit of chemotherapy
in localized soft-tissue sarcomas is at least in part due to the fact
that many trials have included heterogeneous types of sarcomas
with different profiles of chemosensitivity. Several studies
carried out in the metastatic [14–17] or the pediatric settings
[18, 19] have suggested that SS is more chemosensitive than
other soft-tissue sarcoma subtypes. A histology-specific
randomized trial would be the best way to test this hypothesis
in the adjuvant or neo-adjuvant setting. However, SS is a rare
disease representing 80–100 new cases diagnosed yearly in
a country of 60 millions inhabitants such as France. Therefore,
the feasibility of such a trial is clearly compromised by the
difficulties to reach a reasonable accruement goal. Despite the
usual limitations of a retrospective design, this large database
study provides useful insights on the specific issue of the role of
neo-adjuvant and adjuvant chemotherapy in SS. We limited the
potential bias by using adjustment for the significant prognostic
factors. Altogether, our results indicate that neo-adjuvant or
chemotherapy do not alter outcome of patients with primary
SS. It is unlikely that such a lack of benefit of chemotherapy was
the result of a suboptimal treatment. Although, the
chemotherapy regimens used in our series were heterogeneous,
a majority of patients were treated with a dose-optimal
ifosfamide-containing regimen. Moreover, our data are in
agreement with those of two other contemporaneous studies
which also failed to show any impact of adjuvant chemotherapy
on survival of patients with localized SS. A recent pooled
analysis of the two largest randomized trials which assessed the
role of adjuvant chemotherapy in localized high-grade soft-
tissue sarcoma (EORTC 62771 and 62931) has shown that
tumor size, histological grade or histological subtype had no
predictive value for chemotherapy benefit [35]. In particular,
no benefit of adjuvant chemotherapy was observed for the
group of 108 patients with SS [35]. A large Italian single-
institution study also showed that neo-adjuvant and adjuvant
chemotherapy do not improve survival of patients with
localized SS despite the use of an high-dose combination
regimen (ifosfamide 9 g/m2, doxorubicin 80 mg/m2) in the
majority of treated patients [29].
Despite these disappointing results, we cannot exclude
that chemotherapy is of benefit in a subset of patients with
tumors showing some specific biological features. For
instance, the potential predictive value of the fusion types
(SYT-SSX1 or SYT-SSX2) is currently under investigation.
However, our present results indicate that wide surgical
resection and adjuvant radiation therapy when applicable is
still the gold standard of care for patients with SS and that
chemotherapy should not be delivered outside a clinical trial
setting.
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